NCT07521657 2026-04-13
NF118
University of Alabama at Birmingham
Phase 2 Not yet recruiting
Clinical Trials
18 trialsNCT07462507 2026-03-10
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT07439172 2026-02-27
PRC
The Cooper Health System
Phase 2 Not yet recruiting
NCT07356973 2026-01-26
OPTICAL
CRISM Therapeutics LTD
Phase 2 Not yet recruiting
NCT07365280 2026-01-26
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
ZSky Biotech Inc
Phase 2 Not yet recruiting
NCT07284628 2025-12-16
ReVoGlio
University of Zurich
Phase 2 Not yet recruiting
NCT06804655 2025-10-02
EViDENCE-BT
University of Zurich
Phase 2 Not yet recruiting
NCT06492486 2025-09-16
GLADIATOR
Tata Memorial Centre
Phase 2 Not yet recruiting
NCT07138001 2025-08-22
Phase 2 Clinical Trial of KH617
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Phase 2 Not yet recruiting
NCT07047066 2025-07-02
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
Tongji Hospital
Phase 2 Not yet recruiting
NCT01777919 2025-05-25
GLIODIS
Olympion Medical Center
Phase 2 Not yet recruiting
NCT06894225 2025-04-06
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
National Neuroscience Institute
Phase 2 Not yet recruiting
NCT06780592 2025-01-22
Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery
Huashan Hospital
Phase 2 Not yet recruiting
NCT06218524 2024-01-23
The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM
Southern Medical University, China
Phase 2 Not yet recruiting
NCT05820191 2023-12-21
B-amyloid as a Marker for GBM Bioimaging
Universidad Central del Caribe
Phase 2 Not yet recruiting
NCT05540275 2023-10-06
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT05842746 2023-05-06
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT05502991 2022-09-27
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting